RVTY — Revvity, Inc. stock price, charts and financials

QT66Revvity, Inc.

Revvity, Inc. (NYSE: RVTY) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
143.45
-3.28-2.24%
RVTYQT66Revvity, Inc.·NYSE
143.45-2.24%
News
Down 2.2% — Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB) (defenseworld.net).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E68.31EPS (ttm)2.10Insider Own0.50%Shs Outstand111.56MPerf Week15.40%
Market Cap16.00BForward P/E24.37EPS next Y5.89Insider Trans-1.34%Shs Float102.20MPerf Month20.09%
Enterprise Value18.32BPEG7.13EPS next Q1.28Inst Own-Short Float6.17%Perf Quarter43.45%
Income238.00MP/S5.50EPS this Y155.02%Inst Trans-Short Ratio4.33Perf Half Y67.27%
Sales2.91BP/B2.21EPS next Y9.90%ROA1.97%Short Interest6.31MPerf YTD48.27%
Book/sh64.80P/C15.64EPS next 5Y9.58%ROE3.27%52W High149.52 -4.06%Perf Year67.99%
Cash/sh9.17P/FCF24.79EPS past 3/5Y-22.69% -20.37%ROIC2.91%52W Low81.22 76.62%Perf 3Y28.17%
Dividend Est.0.28 (0.20%)EV/EBITDA23.86Sales past 3/5Y-4.82% -5.47%Gross Margin52.11%Volatility4.80% 3.41%Perf 5Y-23.31%
Dividend TTM0.28 (0.20%)EV/Sales6.29EPS Y/Y TTM-12.86%Oper. Margin12.32%ATR (14)4.63Perf 10Y161.53%
Dividend Ex-DateOct 23, 2026Quick Ratio1.50Sales Y/Y TTM5.70%Profit Margin8.16%RSI (14)69.21Recom2.48
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio1.80EPS Q/Q19.49%SMA2010.12%Beta1.05Target Price124.00
Payout13.36%Debt/Eq0.48Sales Q/Q1.39%SMA5019.32%Rel Volume1.99Prev Close146.73
Employees11,000LT Debt/Eq0.40EarningsOct 26SMA20038.08%Avg Volume1.67MPrice143.45
IPO DateJul 06, 1965Option/ShortYes / YesEPS/Sales Surpr.16.16% 1.14%Net Debt/EBITDA3.02Volume3,321,311Change-2.24%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedUBSBuy$120$140
Sep-04-26ReiteratedKeybancOverweight$132$165
Sep-01-26ReiteratedRBC Capital$135
Jul-06-26ReiteratedEvercore ISI GroupOutperform$118$125
Jun-26-26ResumedBernsteinMarket Perform$130$115
May-06-26ReiteratedStifel Nicolaus$110$100
May-06-26ReiteratedRobert W. Baird$125$117
May-04-26ReiteratedRobert W. Baird$129$125
Apr-14-26DowngradeBarclaysOverweightEqual Weight$118$95
Feb-03-26ReiteratedRobert W. Baird$123$129
Latest News· Times ET
Sep-17-26
Sep-16-26
Sep-15-26
Sep-14-26
Sep-11-26
Sep-10-26
Sep-09-26
Sep-04-26
Sep-02-26
Sep-01-26
Aug-25-26
Company

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,9122,8562,755
Cost of Goods Sold Incl. D&A1,3941,3401,432
Gross Profit1,5181,5161,323
Selling, General and Administrative Excl. Other943945715
Research and Development216216197
Other Operating Expense0-20
Operating Income359357411
Interest Expense959296
Unusual Expense
Non-Operating Income (Expense)-442
Net Income Before Taxes262268316
Income Taxes202633
Consolidated Net Income238242296
Net Income From Continuing Operations239242283
Net Income238242296
EPS (Recurring)2.102.082.41
EPS (Basic, Before Extraordinaries)2.102.082.41
EPS (Diluted)2.102.082.41
EBITDA768663840
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio68.3146.5146.47
Price To Sales Ratio5.523.835.00
Gross Margin52.1353.0848.02
Operating Margin12.3312.5014.92
Net Margin8.178.4710.74
Shares Outstanding112113123
Market Capitalization16,06610,93313,775
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$156.40$135.45$114.50$93.54$72.59 Close Price0.00M1.17M2.34M3.50M4.67MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Vohra Tajinder SPlease See RemarksSep 16 '26Sale140.887,3301,032,6506,635Sep 18
Gonzales AnitaVice President and CAOJul 20 '26Sale109.48859,3067,201Jul 22
Gonzales AnitaVice President and CAOApr 20 '26Sale92.80807,4247,319Apr 22
Victor MiriamePlease See RemarksFeb 24 '26Option Exercise95.743,724356,53619,984Feb 26
Victor MiriamePlease See RemarksFeb 24 '26Sale97.131,862180,85618,122Feb 26
McMurry-Heath MichelleDirectorFeb 23 '26Sale97.2660058,3564,233Feb 25
Singh Prahlad R.Please See RemarksFeb 05 '26Sale100.2125,5252,557,859120,213Feb 06
Singh Prahlad R.Please See RemarksFeb 05 '26Option Exercise92.0925,5252,350,597145,738Feb 06
Goldberg Joel SPlease See RemarksFeb 05 '26Option Exercise92.0912,7171,171,10955,964Feb 06
Goldberg Joel SPlease See RemarksFeb 05 '26Sale100.2112,7171,274,35743,247Feb 06
Vohra Tajinder SPlease See RemarksFeb 02 '26Option Exercise92.0911,5121,060,14016,198Feb 04
Vohra Tajinder SPlease See RemarksFeb 02 '26Sale104.505,756601,50210,442Feb 04
MICHAS ALEXIS PDirectorAug 27 '25Sale89.0150044,5057,270Aug 28
McMurry-Heath MichelleDirectorMay 29 '25Sale92.1760055,2994,833May 30
McMurry-Heath MichelleDirectorFeb 06 '25Sale119.491,970235,3953,021Feb 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.